Brief: Sun Pharma Says Unloxcyt Receives Category 2A Designation In NCCN Guidelines For LACSCC
Tue 13:06
BRIEF-Sun Pharma Says Unloxcyt Receives Category 2A Designation In NCCN Guidelines For LACSCC Oct 20 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMA - UNLOXCYT RECEIVES CATEGORY 2A DESIGNATION IN NCCN GUIDELINES FOR LACSCC
SUN PHARMA - UNLOXCYT ELEVATED TO NATIONAL COMPREHENSIVE CANCER NETWORK CATEGORY 2A RECOMMENDED OPTION
Source text: ID:nBSE1dLMb7
Further company coverage: SUN.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Sun Pharmaceutical Industries
See all newsIndia's Sun Pharma misses debt fundraise goal as investors demand higher yields, bankers say
India New Issue-Sun Pharma accepts bids for bond issues, bankers say
Brief: Sun Pharma Says Unloxcyt Receives Category 2A Designation In NCCN Guidelines For LACSCC
India New Issue-Sun Pharma to issue over five-year bonds, bankers say
India's Persistent Systems plans debut rupee debt sale to fund acquisition, bankers say